# US 2025/0093251 A1 · Size-tunable synthetic particles with tunable optical properties and methods for using the same immune cell activation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0093251 A1
- Document ID: US20250093251A1
- Status: Published application
- Kind: A1
- Application number: 18/966,771
- Filed: 2024-12-03
- Published: 2025-03-20
- Earliest claimed: 2022-10-26
- Assignees: Slingshot Biosciences, Inc.
- Applicants: Slingshot Biosciences, Inc.
- Inventors: Daixuan ZHANG; Solomon STONEBLOOM; Juan ARMAS; Harini KETHAR; Sunil THOMAS; Martina DE GEUS
- Web page: https://patentgrep.com/patent/US20250093251A1

## CPC

- G01N 15/0893: {by measuring weight or volume of sorbed fluid, e.g. B.E.T. method}
- G01N 33/532: Production of labelled immunochemicals
- G01N 15/1012: {Calibrating particle analysers; References therefor}
- G01N 15/1459: {the analysis being performed on a sample stream}
- G01N 15/1468: {with spatial resolution of the texture or inner structure of the particle}
- G01N 15/147: {the analysis being performed on a sample stream}
- G01N 33/5005: {involving human or animal cells (immunoassay G01N33/56966; immunoassays of protozoa G01N33/56905; protozoa in screening assays C12Q1/025)}
- G01N 33/533: with fluorescent label
- G01N 33/563: involving antibody fragments
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 2015/0038: {Investigating nanoparticles}
- G01N 2015/1006: {for cytology}
- G01N 2015/1014: {Constitution of reference particles}
- G01N 2015/1493: {Particle size}
- G01N 2015/1497: {Particle shape}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A hydrogel particle, comprising a matrix comprising a polymerized monomer, said matrix comprising a plurality of micropores and a plurality of macropores, and one or more immunostimulatory biomolecules selected from the group consisting of an anti-CD3 antibody or antigen-binding fragment thereof, an anti-CD28 antibody or antigen-binding fragment thereof, and combinations thereof.

## Claims

### Claim 1

A particle for inducing an immune cell response, the particle comprising:
a matrix comprising a polymerized monomer having a plurality of micropores and a plurality of macropores; and
one or more immunostimulatory or co-stimulatory biomolecules, wherein the plurality of macropores comprise an average diameter between about 200 nm and about 2 μm, wherein the particle is capable of inducing the immune cell response when contacted with an immune cell, and wherein the immune cell response comprises activation and/or expansion of the immune cell.

### Claim 2 (depends on 1)

The particle of claim 1, wherein an average diameter of the plurality of micropores is between about 1 nm and about 20 nm.

### Claim 3 (depends on 1)

The particle of claim 1, wherein the average diameter of the plurality of micropores is between about 2 nm and about 4 nm.

### Claim 4 (depends on 1)

The particle of claim 1, wherein the immune cell response from contacting the immune cell with the particle is higher than the immune cell response from a control immune cell contacted with an otherwise identical particle lacking the plurality of macropores.

### Claim 5 (depends on 4)

The particle of claim 4, wherein the immune cell response is determined by IL-2 secretion, CD25 expression, or CD69 expression, from the immune cell.

### Claim 6 (depends on 1)

The particle of claim 1, wherein the immune cell is a T cell.

### Claim 7 (depends on 1)

The particle of claim 1, wherein the immune cell is a cytotoxic T cell.

### Claim 8 (depends on 1)

The particle of claim 1, wherein the immune cell is a chimeric antigen receptor (CAR) T cell.

### Claim 9 (depends on 1)

The particle of claim 1, wherein the particle has a porosity of about 5% to about 95% of a volume of the particle.

### Claim 10 (depends on 1)

The particle of claim 1, wherein the one or more immunostimulatory or co-stimulatory biomolecules are attached to a surface of the matrix via a linker.

### Claim 11 (depends on 10)

The particle of claim 10, wherein the linker comprises streptavidin.

### Claim 12 (depends on 1)

The particle of claim 1, wherein the one or more immunostimulatory or co-stimulatory biomolecules are biotinylated.

### Claim 13 (depends on 1)

The particle of claim 1, wherein the matrix comprises a bifunctional monomer and wherein the one or more immunostimulatory or co-stimulatory biomolecules are attached to the bifunctional monomer.

### Claim 14 (depends on 1)

The particle of claim 1, wherein the one or more immunostimulatory or co-stimulatory biomolecules are selected from the group consisting of an anti-CD3 antibody or antigen-binding fragment thereof, an anti-CD28 antibody or antigen-binding fragment thereof, an anti-CD19 antibody or antigen-binding fragment, an anti-41BBL antibody or antigen-binding fragment, an anti-OX40L antibody or antigen-binding fragment, an anti-CD2 antibody or antigen-binding fragment, an anti-CD335 antibody or antigen-binding fragment, an anti-CD16 antibody or antigen-binding fragment, an anti-CD56 antibody or antigen-binding fragment, an anti-CD20 antibody or antigen-binding fragment, an anti-CD80 antibody or antigen-binding fragment, an anti-CD86 antibody or antigen-binding fragment, an anti-CD69 antibody or antigen-binding fragment, an anti-CD154 antibody or antigen-binding fragment, an anti-CD137 antibody or antigen-binding fragment, an IgM antibody or antigen-binding fragment, an IgG antibody or antigen-binding fragment, an IgE antibody or antigen-binding fragment, an IgA antibody or antigen-binding fragment, an IgD antibody or antigen-binding fragment, a toll-like receptor, and any combination thereof.

### Claim 15 (depends on 1)

The particle of claim 1, wherein the one or more immunostimulatory or co-stimulatory biomolecules are selected from the group consisting of anti-CD19, anti-41BBL, anti-OX40L, anti-CD2, anti-CD335, anti-CD16, anti-CD56, anti-CD20, anti-CD80, anti-CD86, anti-CD69, anti-CD154, anti-CD137, and any combination thereof.

### Claim 16 (depends on 1)

The particle of claim 1, wherein the one or more immunostimulatory or co-stimulatory biomolecules comprise:
an anti-CD3 antibody or an antigen-binding fragment thereof; and/or
an anti-CD28 antibody or an antigen-binding fragment thereof.

### Claim 17 (depends on 1)

The particle of claim 1, wherein the plurality of micropores are formed during monomer polymerization.

### Claim 18 (depends on 1)

The particle of claim 1, wherein the plurality of macropores comprise between about 2% and about 30% of a total number of pores of the particle, the total number of pores of the particle being a combination of the plurality of micropores and the plurality of macropores.

### Claim 19 (depends on 1)

The particle of claim 1, wherein the particle comprises the plurality of macropores at a concentration of at least 2.25% v/v, at least 3.4% v/v, and/or at least 4.5% v/v.

### Claim 20 (depends on 1)

The particle of claim 1, wherein the particle has a diameter of between about 1 μm and about 25 μm.

### Claim 21 (depends on 20)

The particle of claim 20, wherein the particle has a diameter of between about 2 μm and about 5 μm.

### Claim 22

A particle for inducing an immune cell response, the particle comprising:
a matrix comprising a polymerized monomer having a plurality of micropores and a plurality of macropores; and
one or more immunostimulatory or co-stimulatory biomolecules,
wherein the particle is capable of inducing the immune cell response when contacted with an immune cell, wherein the immune cell response comprises activation and/or expansion of the immune cell, and wherein the immune cell response from contacting the immune cell with the particle is higher than the immune cell response from a control immune cell contacted with an otherwise identical particle lacking the plurality of macropores.

### Claim 23 (depends on 22)

The particle of claim 22, wherein an average diameter of the plurality of micropores is between about 1 nm and about 20 nm.

### Claim 24 (depends on 22)

The particle of claim 22, wherein the average diameter of the plurality of micropores is between about 2 nm and about 4 nm.

### Claim 25 (depends on 22)

The particle of claim 22, wherein the immune cell response is determined by IL-2 secretion, CD25 expression, or CD69 expression, from the immune cell.

### Claim 26 (depends on 22)

The particle of claim 22, wherein the immune cell is a T cell.

### Claim 27 (depends on 22)

The particle of claim 22, wherein the immune cell is a cytotoxic T cell.

### Claim 28 (depends on 22)

The particle of claim 22, wherein the immune cell is a chimeric antigen receptor (CAR) T cell.

### Claim 29 (depends on 22)

The particle of claim 22, wherein the particle has a porosity of about 5% to about 95% of a volume of the particle.

### Claim 30 (depends on 22)

The particle of claim 22, wherein the one or more immunostimulatory or co-stimulatory biomolecules are attached to a surface of the matrix via a linker.

### Claim 31 (depends on 30)

The particle of claim 30, wherein the linker comprises streptavidin.

### Claim 32 (depends on 22)

The particle of claim 22, wherein the one or more immunostimulatory or co-stimulatory biomolecules are biotinylated.

### Claim 33 (depends on 22)

The particle of claim 22, wherein the matrix comprises a bifunctional monomer and wherein the one or more immunostimulatory or co-stimulatory biomolecules are attached to the bifunctional monomer.

### Claim 34 (depends on 22)

The particle of claim 22, wherein the one or more immunostimulatory or co-stimulatory biomolecules are selected from the group consisting of an anti-CD3 antibody or antigen-binding fragment thereof, an anti-CD28 antibody or antigen-binding fragment thereof, an anti-CD19 antibody or antigen-binding fragment, an anti-41BBL antibody or antigen-binding fragment, an anti-OX40L antibody or antigen-binding fragment, an anti-CD2 antibody or antigen-binding fragment, an anti-CD335 antibody or antigen-binding fragment, an anti-CD16 antibody or antigen-binding fragment, an anti-CD56 antibody or antigen-binding fragment, an anti-CD20 antibody or antigen-binding fragment, an anti-CD80 antibody or antigen-binding fragment, an anti-CD86 antibody or antigen-binding fragment, an anti-CD69 antibody or antigen-binding fragment, an anti-CD154 antibody or antigen-binding fragment, an anti-CD137 antibody or antigen-binding fragment, an IgM antibody or antigen-binding fragment, an IgG antibody or antigen-binding fragment, an IgE antibody or antigen-binding fragment, an IgA antibody or antigen-binding fragment, an IgD antibody or antigen-binding fragment, a toll-like receptor, and any combination thereof.

### Claim 35 (depends on 22)

The particle of claim 22, wherein the one or more immunostimulatory or co-stimulatory biomolecules are selected from the group consisting of anti-CD19, anti-41BBL, anti-OX40L, anti-CD2, anti-CD335, anti-CD16, anti-CD56, anti-CD20, anti-CD80, anti-CD86, anti-CD69, anti-CD154, anti-CD137, and any combination thereof.

### Claim 36 (depends on 22)

The particle of claim 22, wherein the one or more immunostimulatory or co-stimulatory biomolecules comprise:
an anti-CD3 antibody or an antigen-binding fragment thereof; and/or
an anti-CD28 antibody or an antigen-binding fragment thereof.

### Claim 37 (depends on 22)

The particle of claim 22, wherein the plurality of micropores are formed during monomer polymerization.

### Claim 38 (depends on 22)

The particle of claim 22, wherein the plurality of macropores comprise between about 2% and about 30% of a total number of pores of the particle, the total number of pores of the particle being a combination of the plurality of micropores and the plurality of macropores.

### Claim 39 (depends on 22)

The particle of claim 22, wherein the particle comprises the plurality of macropores at a concentration of at least 2.25% v/v, at least 3.4% v/v, and/or at least 4.5% v/v.

### Claim 40 (depends on 22)

The particle of claim 22, wherein the particle has a diameter of between about 1 μm and about 25 μm.

### Claim 41 (depends on 40)

The particle of claim 40, wherein the particle has a diameter of between about 2 μm and about 5 μm.

### Claim 42

A particle for inducing an immune cell response, the particle comprising:
a matrix comprising a polymerized monomer having a plurality of micropores and a plurality of macropores; and
one or more immunostimulatory or co-stimulatory biomolecules,
wherein the particle is capable of inducing the immune cell response when contacted with an immune cell, wherein the immune cell response comprises activation and/or expansion of the immune cell, and wherein the plurality of micropores are formed during monomer polymerization.

### Claim 43 (depends on 42)

The particle of claim 42, wherein an average diameter of the plurality of micropores is between about 1 nm and about 20 nm.

### Claim 44 (depends on 42)

The particle of claim 42, wherein the average diameter of the plurality of micropores is between about 2 nm and about 4 nm.

### Claim 45 (depends on 42)

The particle of claim 42, wherein the immune cell response from contacting the immune cell with the particle is higher than the immune cell response from a control immune cell contacted with an otherwise identical particle lacking the plurality of macropores, and wherein the immune cell response is determined by IL-2 secretion, CD25 expression, or CD69 expression, from the immune cell.

### Claim 46 (depends on 42)

The particle of claim 42, wherein the immune cell is a T cell.

### Claim 47 (depends on 42)

The particle of claim 42, wherein the immune cell is a cytotoxic T cell.

### Claim 48 (depends on 42)

The particle of claim 42, wherein the immune cell is a chimeric antigen receptor (CAR) T cell.

### Claim 49 (depends on 42)

The particle of claim 42, wherein the particle has a porosity of about 5% to about 95% of a volume of the particle.

### Claim 50 (depends on 42)

The particle of claim 42, wherein the one or more immunostimulatory or co-stimulatory biomolecules are attached to a surface of the matrix via a linker.

### Claim 51 (depends on 50)

The particle of claim 50, wherein the linker comprises streptavidin.

### Claim 52 (depends on 42)

The particle of claim 42, wherein the one or more immunostimulatory or co-stimulatory biomolecules are biotinylated.

### Claim 53 (depends on 42)

The particle of claim 42, wherein the matrix comprises a bifunctional monomer and wherein the one or more immunostimulatory or co-stimulatory biomolecules are attached to the bifunctional monomer.

### Claim 54 (depends on 42)

The particle of claim 42, wherein the one or more immunostimulatory or co-stimulatory biomolecules are selected from the group consisting of an anti-CD3 antibody or antigen-binding fragment thereof, an anti-CD28 antibody or antigen-binding fragment thereof, an anti-CD19 antibody or antigen-binding fragment, an anti-41BBL antibody or antigen-binding fragment, an anti-OX40L antibody or antigen-binding fragment, an anti-CD2 antibody or antigen-binding fragment, an anti-CD335 antibody or antigen-binding fragment, an anti-CD16 antibody or antigen-binding fragment, an anti-CD56 antibody or antigen-binding fragment, an anti-CD20 antibody or antigen-binding fragment, an anti-CD80 antibody or antigen-binding fragment, an anti-CD86 antibody or antigen-binding fragment, an anti-CD69 antibody or antigen-binding fragment, an anti-CD154 antibody or antigen-binding fragment, an anti-CD137 antibody or antigen-binding fragment, an IgM antibody or antigen-binding fragment, an IgG antibody or antigen-binding fragment, an IgE antibody or antigen-binding fragment, an IgA antibody or antigen-binding fragment, an IgD antibody or antigen-binding fragment, a toll-like receptor, and any combination thereof.

### Claim 55 (depends on 42)

The particle of claim 42, wherein the one or more immunostimulatory or co-stimulatory biomolecules are selected from the group consisting of anti-CD19, anti-41BBL, anti-OX40L, anti-CD2, anti-CD335, anti-CD16, anti-CD56, anti-CD20, anti-CD80, anti-CD86, anti-CD69, anti-CD154, anti-CD137, and any combination thereof.

### Claim 56 (depends on 42)

The particle of claim 42, wherein the one or more immunostimulatory or co-stimulatory biomolecules comprise:
an anti-CD3 antibody or an antigen-binding fragment thereof; and/or
an anti-CD28 antibody or an antigen-binding fragment thereof.

### Claim 57 (depends on 42)

The particle of claim 42, wherein the plurality of macropores comprise between about 2% and about 30% of a total number of pores of the particle, the total number of pores of the particle being a combination of the plurality of micropores and the plurality of macropores.

### Claim 58 (depends on 42)

The particle of claim 42, wherein the particle comprises the plurality of macropores at a concentration of at least 2.25% v/v, at least 3.4% v/v, and/or at least 4.5% v/v.

### Claim 59 (depends on 42)

The particle of claim 42, wherein the particle has a diameter of between about 1 μm and about 25 μm.

### Claim 60 (depends on 59)

The particle of claim 59, wherein the particle has a diameter of between about 2 μm and about 5 μm.

### Claim 61

A particle for inducing an immune cell response, the particle comprising:
a matrix comprising a polymerized monomer having a plurality of micropores and a plurality of macropores; and
one or more immunostimulatory or co-stimulatory biomolecules,
wherein the particle is capable of inducing the immune cell response when contacted with an immune cell, wherein the immune cell response comprises activation and/or expansion of the immune cell, and wherein the particle has a diameter of between about 1 μm and about 25 μm.

### Claim 62 (depends on 61)

The particle of claim 61, wherein an average diameter of the plurality of micropores is between about 1 nm and about 20 nm.

### Claim 63 (depends on 61)

The particle of claim 61, wherein the average diameter of the plurality of micropores is between about 2 nm and about 4 nm.

### Claim 64 (depends on 61)

The particle of claim 61, wherein the immune cell response from contacting the immune cell with the particle is higher than the immune cell response from a control immune cell contacted with an otherwise identical particle lacking the plurality of macropores, and wherein the immune cell response is determined by IL-2 secretion, CD25 expression, or CD69 expression, from the immune cell.

### Claim 65 (depends on 61)

The particle of claim 61, wherein the immune cell is a T cell.

### Claim 66 (depends on 61)

The particle of claim 61, wherein the immune cell is a cytotoxic T cell.

### Claim 67 (depends on 61)

The particle of claim 61, wherein the immune cell is a chimeric antigen receptor (CAR) T cell.

### Claim 68 (depends on 61)

The particle of claim 61, wherein the particle has a porosity of about 5% to about 95% of a volume of the particle.

### Claim 69 (depends on 61)

The particle of claim 61, wherein the one or more immunostimulatory or co-stimulatory biomolecules are attached to a surface of the matrix via a linker.

### Claim 70 (depends on 69)

The particle of claim 69, wherein the linker comprises streptavidin.

### Claim 71 (depends on 61)

The particle of claim 61, wherein the one or more immunostimulatory or co-stimulatory biomolecules are biotinylated.

### Claim 72 (depends on 61)

The particle of claim 61, wherein the matrix comprises a bifunctional monomer and wherein the one or more immunostimulatory or co-stimulatory biomolecules are attached to the bifunctional monomer.

### Claim 73 (depends on 61)

The particle of claim 61, wherein the one or more immunostimulatory or co-stimulatory biomolecules are selected from the group consisting of an anti-CD3 antibody or antigen-binding fragment thereof, an anti-CD28 antibody or antigen-binding fragment thereof, an anti-CD19 antibody or antigen-binding fragment, an anti-41BBL antibody or antigen-binding fragment, an anti-OX40L antibody or antigen-binding fragment, an anti-CD2 antibody or antigen-binding fragment, an anti-CD335 antibody or antigen-binding fragment, an anti-CD16 antibody or antigen-binding fragment, an anti-CD56 antibody or antigen-binding fragment, an anti-CD20 antibody or antigen-binding fragment, an anti-CD80 antibody or antigen-binding fragment, an anti-CD86 antibody or antigen-binding fragment, an anti-CD69 antibody or antigen-binding fragment, an anti-CD154 antibody or antigen-binding fragment, an anti-CD137 antibody or antigen-binding fragment, an IgM antibody or antigen-binding fragment, an IgG antibody or antigen-binding fragment, an IgE antibody or antigen-binding fragment, an IgA antibody or antigen-binding fragment, an IgD antibody or antigen-binding fragment, a toll-like receptor, and any combination thereof.

### Claim 74 (depends on 61)

The particle of claim 61, wherein the one or more immunostimulatory or co-stimulatory biomolecules are selected from the group consisting of anti-CD19, anti-41BBL, anti-OX40L, anti-CD2, anti-CD335, anti-CD16, anti-CD56, anti-CD20, anti-CD80, anti-CD86, anti-CD69, anti-CD154, anti-CD137, and any combination thereof.

### Claim 75 (depends on 61)

The particle of claim 61, wherein the one or more immunostimulatory or co-stimulatory biomolecules comprise:
an anti-CD3 antibody or an antigen-binding fragment thereof; and/or
an anti-CD28 antibody or an antigen-binding fragment thereof.

### Claim 76 (depends on 61)

The particle of claim 61, wherein the plurality of macropores comprise between about 2% and about 30% of a total number of pores of the particle, the total number of pores of the particle being a combination of the plurality of micropores and the plurality of macropores.

### Claim 77 (depends on 61)

The particle of claim 61, wherein the particle comprises the plurality of macropores at a concentration of at least 2.25% v/v, at least 3.4% v/v, and/or at least 4.5% v/v.

### Claim 78 (depends on 61)

The particle of claim 61, wherein the particle has a diameter of between about 2 μm and about 5 μm.
